Gustave Roussy accelerate the development of innovative anticancer treatments by expanding its portfolio of privileged global partnerships
Gustave Roussy and AbbVie have entered into a three-year strategic scientific alliance aimed at accelerating the development of innovative cancer therapies.
On
Gustave Roussy today announced a three-year strategic scientific alliance with AbbVie that aims to accelerate the development of new cancer treatments and expand therapeutic options for patients in France and worldwide.
By combining AbbVie’s oncology research expertise and broad therapeutic pipeline with Gustave Roussy’s internationally recognised capabilities in translational research, early drug development and clinical research, the alliance will seek to advance scientific discoveries into potential new treatment approaches for cancers with high unmet medical needs.
The partnership will support joint translational and clinical research programmes across multiple stages of development. It will bring together scientists and clinicians from both organisations to identify new areas of collaboration, generate scientific evidence and accelerate the translation of research findings into potential therapeutic advances for patients.
“At Gustave Roussy, our ambition is to transform the most promising scientific discoveries into tangible advances for patients. Being selected as AbbVie’s first partner outside the United States for a global alliance of this scope is a strong recognition of Gustave Roussy’s scientific leadership and capacity for innovation,” said Professor Fabrice Barlesi, Chief Executive Officer of Gustave Roussy. “By combining the strengths of a global biopharmaceutical leader with the leading Europe’s cancer centre, we are creating the conditions needed to accelerate the development of innovative therapeutic approaches. This alliance also demonstrates the ability of French and European research to establish world-class collaborations addressing some of the most pressing challenges in oncology.”
Scientific teams from both organisations will subsequently work together to potentially identify and launch projects in lung, gastrointestinal and gynaecological cancers. These projects are expected to include translational research conducted through the UNLOCK programme led by the PRISM Institute.
This strategic alliance builds on an established relationship between Gustave Roussy and AbbVie through AbbVie’s Phase 1 Partnerships for Excellence in Research, known as the P1PER network. P1PER is a global network of leading oncology clinical trial centres designed to accelerate the early development of novel therapies for difficult-to-treat haematological malignancies and solid tumours.
“This alliance represents the next chapter of our collaboration with Gustave Roussy and reflects our collective ambition to accelerate oncology innovation for people living with cancer,” said Eleni Lagkadinou, Vice President, Oncology Early Development at AbbVie. “By combining our complementary expertise and strength in translational research and clinical development, we aim to advance promising research into potential new treatment options for people living with cancer.
Press contact
If you are a journalist and have a question, please contact:
Claire Parisel or Léona Pinto
Tel. +33 1 42 11 50 59
Tel. +33 1 42 11 63 59
Mob. +33 6 17 66 00 26
Email
The Media Team cannot respond to patient inquiries.